Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)–revised recommendations of the Neuromyelitis Optica Study Group …
T Kümpfel, K Giglhuber, O Aktas, I Ayzenberg… - Journal of …, 2024 - Springer
This manuscript presents practical recommendations for managing acute attacks and
implementing preventive immunotherapies for neuromyelitis optica spectrum disorders …
implementing preventive immunotherapies for neuromyelitis optica spectrum disorders …
[HTML][HTML] A comprehensive review of the advances in neuromyelitis optica spectrum disorder
P Siriratnam, S Huda, H Butzkueven… - Autoimmunity …, 2023 - Elsevier
Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing neuroinflammatory
autoimmune astrocytopathy, with a predilection for the optic nerves and spinal cord. Most …
autoimmune astrocytopathy, with a predilection for the optic nerves and spinal cord. Most …
Long‐term safety and efficacy of Eculizumab in Aquaporin‐4 IgG‐positive NMOSD
DM Wingerchuk, K Fujihara, J Palace… - Annals of …, 2021 - Wiley Online Library
Objective During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk
versus placebo in patients with aquaporin‐4 immunoglobulin G‐positive neuromyelitis …
versus placebo in patients with aquaporin‐4 immunoglobulin G‐positive neuromyelitis …
Progress in treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD
M Shi, F Chu, T Jin, J Zhu - CNS Neuroscience & Therapeutics, 2022 - Wiley Online Library
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory
demyelinating disorder of the central nervous system (CNS), which is a severely disabling …
demyelinating disorder of the central nervous system (CNS), which is a severely disabling …
The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders
P Stathopoulos, MC Dalakas - Expert review of clinical immunology, 2022 - Taylor & Francis
Introduction Neuromyelitis optica spectrum disorders (NMOSD) are characterized in the
majority of cases by the presence of IgG1 autoantibodies against aquaporin 4 (AQP4) and …
majority of cases by the presence of IgG1 autoantibodies against aquaporin 4 (AQP4) and …
In utero exposure to maternal anti–aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring
S Mader, L Brimberg, A Vo, JJ Strohl… - Science translational …, 2022 - science.org
The fetal brain is constantly exposed to maternal IgG before the formation of an effective
blood-brain barrier (BBB). Here, we studied the consequences of fetal brain exposure to an …
blood-brain barrier (BBB). Here, we studied the consequences of fetal brain exposure to an …
Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder
SJ Pittock, M Barnett, JL Bennett, A Berthele… - Annals of …, 2023 - Wiley Online Library
Objective CHAMPION‐NMOSD (NCT04201262) is a phase 3, open‐label, externally
controlled interventional study evaluating the efficacy and safety of the terminal complement …
controlled interventional study evaluating the efficacy and safety of the terminal complement …
Adverse events in NMOSD therapy
K Giglhuber, A Berthele - International journal of molecular sciences, 2022 - mdpi.com
Neuromyelitis optica spectrum disorders (NMOSD) are rare neurologic autoimmune
diseases that have a poor prognosis if left untreated. For many years, generic oral …
diseases that have a poor prognosis if left untreated. For many years, generic oral …
Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges
C Liu, M Shi, M Zhu, F Chu, T Jin, J Zhu - Autoimmunity Reviews, 2022 - Elsevier
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease
of the central nervous system (CNS) associated with autoantibody (ab) to aquaporin-4 …
of the central nervous system (CNS) associated with autoantibody (ab) to aquaporin-4 …
Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder
DM Wingerchuk, BG Weinshenker… - Journal of managed …, 2022 - jmcp.org
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune
disorder affecting the central nervous system that is associated with significant morbidity and …
disorder affecting the central nervous system that is associated with significant morbidity and …